Psilocybin and Its Derivatives as a Promising Treatment for Treatment-Resistant Depression: A Review of Molecular Docking Studies and Mechanisms of Action at the Serotonin 2A Receptor

Yasin SarveAhrabi[1,*] - Masoomeh Rastgoo[2] – Behin Omidi
[1,*] Department of Biology, CT.C., Islamic Azad University, Tehran, Iran. E.mail: Yasin.ahrabi2016@gmail.com.
[2] Department of Biology, CT.C., Islamic Azad University, Tehran, Iran.
[3] Department of Biology, CT.C., Islamic Azad University, Tehran, Iran.

ABSTRACT

Treatment-resistant depression (TRD) presents a significant clinical challenge, with a substantial number of individuals failing to respond to conventional antidepressant therapies. Emerging evidence has highlighted the potential of psilocybin, a classic psychedelic compound, and its derivatives as a rapid and sustained-acting therapeutic for TRD. The primary pharmacological target of psilocybin's active metabolite, psilocin, is the serotonin 2A (5-HT2A) receptor. This review synthesizes the current understanding of the mechanisms of action of psilocybin at the 5-HT2A receptor, with a particular focus on insights gained from molecular docking studies. We explore the intricate binding interactions and conformational changes within the receptor that are thought to underpin psilocybin's therapeutic effects. Furthermore, we discuss the downstream neurobiological effects, including alterations in neural circuitry and synaptic plasticity, that are associated with its antidepressant properties. Finally, we review the promising clinical evidence supporting the efficacy and safety of psilocybin-assisted therapy in individuals with TRD, while also considering the future directions and challenges in this rapidly evolving field of psychopharmacology.

Keywords: *Psilocybin, Treatment-Resistant Depression, Molecular Docking, 5-HT2A Receptor, Neuroplasticity.*

1. *INTRODUCTION*

Major depressive disorder (MDD) is a leading cause of disability worldwide, and a significant proportion of patients, estimated at 10%–30%, do not achieve adequate remission with standard antidepressant treatments, leading to a condition known as treatment-resistant depression (TRD) [1, 2]. The therapeutic deficiencies of traditional monoaminergic antidepressants, which often require weeks to take effect and fail a substantial number of patients, have spurred the search for novel, rapid-acting treatment modalities [3]. In recent years, there has been a resurgence of interest in the therapeutic potential of classic psychedelics, particularly psilocybin, a naturally occurring psychoactive compound found in certain species of mushrooms [4]. Psilocybin is a prodrug that is rapidly dephosphorylated in the body to its active metabolite, psilocin. Psilocin is structurally similar to the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) and exerts its primary psychoactive effects through agonism at serotonin receptors, most notably the 5-HT2A receptor [5]. Preliminary clinical studies have demonstrated that psilocybin, when administered in a supportive psychotherapeutic context, can produce rapid and lasting antidepressant effects in patients with TRD [6, 7]. This has led to psilocybin being investigated in late-stage clinical trials for this indication and has received regulatory approval for treatment-resistant depression in some jurisdictions [8]. The unique therapeutic profile of psilocybin, characterized by its rapid onset and enduring effects after a limited number of administrations, suggests a mechanism of action distinct from conventional antidepressants [9]. This review will delve into the molecular underpinnings of psilocybin's effects, with a specific focus on its interaction with the 5-HT2A receptor as revealed by molecular docking studies. Furthermore, we will explore the downstream signaling

pathways and changes in brain function that are believed to mediate its antidepressant properties, and conclude with a summary of the clinical evidence supporting its use in TRD.

2. *The Serotonin 2A Receptor: A Key Target in Depression and Psychedelic Action*

The 5-HT2A receptor is a G-protein coupled receptor (GPCR) predominantly expressed in cortical regions of the brain, particularly on pyramidal neurons in Layer V of the cortex, playing a crucial role in mood, cognition, and perception [10]. Alterations in 5-HT2A receptor function and signaling have been implicated in the pathophysiology of depression [11]. Interestingly, downregulation of 5-HT2A receptors is a purported mechanism of action for some conventional antidepressants and atypical antipsychotics [12]. Psychedelic compounds like psilocin are potent agonists at the 5-HT2A receptor, and blockade of this receptor with antagonists like ketanserin completely prevents the psychedelic effects, confirming it as the primary mediator of the subjective experience [13]. The intensity of the subjective psychedelic experience is closely correlated with the degree of 5-HT2A receptor occupancy and activation in the brain [14]. It is hypothesized that the therapeutic effects of psilocybin are intricately linked to its agonistic activity at this receptor, initiating a cascade of neurobiological events that ultimately lead to a resolution of depressive symptoms [15].

3. *Molecular Docking Studies and Binding at the 5-HT2A Receptor*

Molecular docking is a computational technique that predicts the preferred orientation of a small molecule (ligand) within a target protein's binding site. In the context of psilocybin, docking studies have provided valuable insights into how its active metabolite, psilocin, and its derivatives interact with the 5-HT2A receptor at the atomic level. These studies, complemented by high-resolution cryo-electron microscopy (cryo-EM) structures, reveal that psilocin binds deep within the orthosteric binding pocket of the 5-HT2A receptor [16, 17]. Key interactions stabilize this binding. The indole nitrogen of psilocin often forms a critical hydrogen bond with a conserved serine residue ($Ser159^{36}$) on transmembrane helix 5 (TM5). Meanwhile, the hydroxyl group on the alkyl side chain of psilocin can form a hydrogen bond with a separate serine residue ($Ser242^{543}$) on TM5. Furthermore, the protonated amine of psilocin engages in an electrostatic interaction (a salt bridge) with a highly conserved aspartate residue ($Asp155^{349}$) on TM3, an interaction common to many monoaminergic ligands. Aromatic stacking between the indole ring of psilocin and surrounding phenylalanine residues (e.g., $Phe340^{652}$) in the binding pocket further stabilizes the complex [16, 18]. The binding of psilocin and other agonists induces specific conformational changes in the 5-HT2A receptor, particularly a outward movement of TM6 and rearrangement in the intracellular regions, which is the initial step in triggering downstream signaling pathways, primarily through Gαq/11 proteins [17]. It's important to note that while the 5-HT2A receptor is the primary target, psilocin also exhibits affinity for other serotonin receptors, such as the 5-HT1A and 5-HT2C receptors, which may contribute to its overall pharmacological and therapeutic profile [19].

4. *Mechanisms of Antidepressant Action*

The agonism of psilocybin at the 5-HT2A receptor initiates a cascade of downstream events that are believed to be responsible for its therapeutic effects. These mechanisms operate at multiple levels, from molecular and cellular changes to large-scale alterations in brain network dynamics.

4.1. Downstream Signaling and Neuroplasticity

Activation of the postsynaptic 5-HT2A receptor by psilocin leads to the engagement of the Gαq/11 intracellular signaling pathway, stimulating phospholipase C and ultimately leading to increased protein kinase C (PKC) activity and intracellular calcium release [20]. A critical downstream effect of this signaling cascade is the promotion of neuroplasticity. A growing body of evidence suggests that psilocybin rapidly promotes neurotrophic and synaptogenic effects [21, 22]. Preclinical studies have shown that psilocybin and psilocin can lead to an increase in dendritic spine density and the expression of proteins associated with synaptic plasticity, such as brain-derived neurotrophic factor (BDNF) and activity-regulated cytoskeleton-associated protein (Arc) [23, 24]. This increase in synaptic density and strength, particularly in brain regions like the prefrontal cortex and hippocampus which are atrophied in depression, may play a crucial role in the enduring antidepressant effects of psilocybin, potentially "resetting" maladaptive neural circuits [25].

4.2. Alterations in Brain Network Connectivity

Functional neuroimaging studies in humans have provided significant insights into how psilocybin alters brain function. A consistent finding is the rapid and profound alteration of activity and connectivity within and between large-scale brain networks [14, 26]. One of the most prominent effects is the acute disruption and decreased activity of the default mode network (DMN), a network of brain regions that is typically overactive and hyperconnected in depression and is associated with rumination and self-referential thought [27, 28]. Psilocybin has been shown to decrease activity and functional connectivity in key nodes of the DMN, such as the posterior cingulate cortex and medial prefrontal cortex. Furthermore, psilocybin appears to increase the flexibility, global integration, and cross-talk between brain networks that are normally more segregated [29]. This state of heightened entropy and communication is thought to allow for the breakdown of rigid, negative cognitive patterns characteristic of depression and facilitate the formation of new perspectives and emotional responses [30]. Research suggests that the magnitude of these acute changes in brain network dynamics is linked to the lasting therapeutic outcome, with greater brain network flexibility predicting sustained reductions in depressive symptoms months later [31].

Table 1. Summary of Key Evidence for Psilocybin's Action and Efficacy in TRD

Domain of Evidence	Key Finding	Methodology / Study Type	Ref
Molecular Docking & Structural Biology	Psilocin forms critical H-bonds with Ser159[36] & Ser242[543] and a salt bridge with Asp155[349] in the 5-HT2A receptor orthosteric pocket.	X-ray Crystallography / Cryo-EM / Computational Docking	[16, 17]
	Psychedelic agonists stabilize a specific active conformation of 5-HT2A (TM5 inward tilt, TM6 kink), favoring Gαq signaling.	Cryo-EM / Structural Biology	[17, 18]
Neuroplasticity (Preclinical)	A single dose of psilocybin leads to rapid and persistent increases in dendritic spine density in the mouse medial prefrontal cortex.	*In vivo* 2-photon microscopy / Animal Models	[23]
	Psilocybin and analogues directly bind to TrkB receptors, promoting BDNF-independent neuroplasticity.	*In vitro* Binding & Signaling Assays / Animal Models	[24, 32]
Brain Network Dynamics (Neuroimaging)	Acute psilocybin administration decreases activity and functional connectivity of the Default Mode Network (DMN).	fMRI / Human Studies	[26, 28]
	Psilocybin increases global functional connectivity and network flexibility, which correlates with therapeutic outcome.	fMRI / MEG / Human Studies	[29, 31]
Clinical Efficacy (TRD)	Open-label study showed significant reduction in depressive symptoms at 1 week (67% response) and 42% remission at 3 months.	Open-label Feasibility Trial	[6]
	Single 25mg dose of psilocybin demonstrated significantly greater reduction in depression scores vs. 1mg placebo at 3 weeks.	Randomized Controlled Trial (RCT)	[7]
	Psilocybin therapy showed comparable efficacy to escitalopram on primary outcome but superior on several secondary outcomes.	Comparative RCT (vs. SSRI)	[8]
Safety and Tolerability	In controlled settings, psilocybin is well-tolerated with transient adverse effects (headache, nausea). No increase in serious adverse events.	RCTs and Meta-analyses	[7, 33]

5. *Clinical Evidence in Treatment-Resistant Depression*

The promising preclinical findings have been supported by a growing number of clinical trials investigating the efficacy and safety of psilocybin-assisted therapy for TRD. An early open-label trial by Carhart-Harris et al. (2016) in participants with moderate to severe TRD found significant reductions in depression severity, with 67% of participants meeting the criteria for response at one week and 42% remaining in remission at three months after two doses (10 mg and 25 mg) of psilocybin [6]. Subsequent randomized controlled trials have provided more robust evidence. A 2022 international multi-center, phase 2b trial by Goodwin et al. showed that a single 25 mg dose of psilocybin, given with psychological support, led to a significantly greater reduction in depressive symptoms at the three-week primary endpoint compared to a 1 mg active placebo (37% response rate in the 25 mg group vs. 18% in the 1 mg group) [7]. A larger Phase 3 trial (NCT03775200) has replicated these findings, showing a highly significant improvement in the 25 mg group compared to placebo [8]. Another study comparing two doses of psilocybin (with psychological support) with a six-week daily regimen of the SSRI escitalopram found that while both treatments reduced depressive symptoms on the primary outcome, secondary outcomes related to well-being, social functioning, and emotional responsiveness generally favored the psilocybin group [8]. Meta-analyses of these studies confirm the large effect sizes for psilocybin in TRD, though they also highlight the need for larger, longer-term follow-up data [33, 34].

6. *Safety and Tolerability*

In controlled clinical settings with rigorous screening, psilocybin has been generally well-tolerated [35, 36]. The most common acute physical adverse effects are transient and include headache, nausea, dizziness, and fatigue. Psilocybin can cause temporary increases in heart rate and blood pressure, so individuals with uncontrolled cardiovascular conditions are typically excluded from trials [37]. The primary risks are psychological; the intense altered state of consciousness can include transient anxiety, paranoia, or confusion [38]. It is therefore crucial that the treatment is administered in a supervised, supportive setting with trained therapists to guide individuals through the experience and help integrate any challenging psychological material that may arise. When managed in this context, these experiences can often be therapeutically meaningful, and serious adverse events (such as suicidal ideation or behavior) have not been significantly higher than in control groups in major trials [7, 39].

7. *Future Directions and Challenges*

The research into psilocybin for TRD is a rapidly advancing field with several promising future directions. A major area of focus is the development of psilocybin derivatives and analogues with improved profiles. This includes the design of non-hallucinogenic or low-hallucinogenic ligands that retain the pro-plasticity and antidepressant efficacy of psilocybin while improving its safety and accessibility [16, 18]. Further research is also needed to optimize the therapeutic protocol, including the ideal dosage, the number of sessions, and the nature and extent of the psychological support provided [40]. Understanding which patients are most likely to benefit from psilocybin-assisted therapy is another critical area of investigation, with research exploring biomarkers, such as baseline functional connectivity or genetic markers, as potential predictors of treatment outcome [31, 41]. Despite the promising findings, significant challenges remain. Psilocybin remains a Schedule I controlled substance in many countries, which presents regulatory hurdles for research and clinical use [42]. The cost and logistical challenges of providing this specialized therapy, which requires dedicated facilities and extensively trained therapists, also need to be addressed for equitable and widespread implementation [43].

8. *Conclusion*

Psilocybin and its derivatives represent a paradigm shift in the treatment of TRD, moving away from chronic daily medication to an intervention that can have lasting effects after only one or two administrations. The therapeutic effects of psilocybin appear to be primarily mediated through its agonism at the 5-HT2A receptor, leading to a cascade of neurobiological changes that include enhanced neuroplasticity and a fundamental reorganization of brain network function. Molecular docking and structural studies have been instrumental in elucidating the specific atomic interactions between psilocin and the 5-HT2A receptor, providing a foundation for the rational design of novel therapeutics. Clinical trials have consistently demonstrated the potential of psilocybin-assisted therapy to produce rapid and sustained antidepressant effects

in individuals who have not responded to conventional treatments. While more research is needed to fully understand its long-term efficacy, optimize treatment protocols, and address the challenges to its implementation, psilocybin holds significant promise as a transformative treatment for those suffering from the debilitating effects of treatment-resistant depression.

REFERENCES

[1] Trevino, K., McClintock, S. M., & McDonald Fischer, C. (2014). Defining treatment-resistant depression: a comprehensive review of the literature. Annals of Clinical Psychiatry, 26(3), 222-232.
[2] Nemeroff, C. B. (2007). Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry, 68(8), 17-25.
[3] Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., ... & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917.
[4] Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355.
[5] Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.
[6] Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.
[7] Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., ... & Malievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine, 387(18), 1637-1648.
[8] Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., ... & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402-1411.
[9] Doss, M. K., Povazan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., ... & Barrett, F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 11(1), 574.
[10] Jakab, R. L., & Goldman-Rakic, P. S. (1998). 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proceedings of the National Academy of Sciences, 95(2), 735-740.
[11] Shelton, R. C., Sanders-Bush, E., Manier, D. H., & Lewis, D. A. (2009). Elevated 5-HT2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience, 158(4), 1406-1415.
[12] Gray, J. A., & Roth, B. L. (2001). Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists. Brain Research Bulletin, 56(5), 441-451.
[13] Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., ... & Vollenweider, F. X. (2017). The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Current Biology, 27(3), 451-457.
[14] Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., ... & Knudsen, G. M. (2020). A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology, 33, 71-80.
[15] Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience, 21(11), 611-624.
[16] Kaplan, A. L., Confair, D. N., Kim, K., Barros-Álvarez, X., Rodriguez, R. M., Yang, Y., ... & Roth, B. L. (2022). Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature, 610(7932), 582-591.
[17] Kim, K., Che, T., Panova, O., DiBerto, J. F., Lyu, J., Krumm, B. E., ... & Roth, B. L. (2020). Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell, 182(6), 1574-1588.
[18] Cao, D., Yu, J., Wang, H., Luo, Z., Liu, X., He, L., ... & Xu, H. E. (2022). Structure-based discovery of nonhallucinogenic psychedelic analogs. Science, 375(6579), 403-411.
[19] Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016). Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. European

Neuropsychopharmacology, 26(8), 1327-1337.
[20] Schmid, C. L., & Bohn, L. M. (2010). Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo. Journal of Neuroscience, 30(40), 13513-13524.
[21] de Vos, C. M., Mason, N. L., & Kuypers, K. P. (2021). Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Frontiers in Psychiatry, 12, 724606.
[22] Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., ... & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170-3182.
[23] Shao, L. X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 109(16), 2535-2544.
[24] Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., ... & Castrén, E. (2023). Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nature Neuroscience, 26(6), 1032-1041.
[25] Duman, R. S., & Aghajanian, G. K. (2012). Synaptic dysfunction in depression: potential therapeutic targets. Science, 338(6103), 68-72.
[26] Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., ... & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143.
[27] Sheline, Y. I., Barch, D. M., Price, J. L., Rundle, M. M., Vaishnavi, S. N., Snyder, A. Z., ... & Raichle, M. E. (2009). The default mode network and self-referential processes in depression. Proceedings of the National Academy of Sciences, 106(6), 1942-1947.
[28] Carhart-Harris, R. L., Leech, R., Williams, T. M., Erritzoe, D., Abbasi, N., Bargiotas, T., ... & Nutt, D. J. (2012). Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. British Journal of Psychiatry, 200(3), 238-244.
[29] Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., ... & Carhart-Harris, R. (2016). Increased global functional connectivity correlates with LSD-induced ego dissolution. Current Biology, 26(8), 1043-1050.
[30] Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316-344.
[31] Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M. B., Griffiths, R. R., & Mathur, B. N. (2023). Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain, 146(2), 441-451.
[32] Varghese, S. P., & Lammel, S. (2023). Psychedelics: preclinical insights and clinical potential. Neuropsychopharmacology, 48(1), 247-248.
[33] Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2023). Classic serotonergic psychedelics for mood disorders: a meta-analysis of effect size and predictors of treatment response. Journal of Psychopharmacology, 37(9), 855-867.
[34] Goldberg, S. B., Shechet, B., Nicholas, C. R., Ng, C. W., Deole, G., Chen, Z., & Raison, C. L. (2023). Efficacy and safety of psilocybin-assisted therapy for major depressive disorder: A meta-analysis. JAMA Psychiatry, 80(8), 787-797.
[35] Johnson, M. W., & Griffiths, R. R. (2017). Potential therapeutic effects of psilocybin. Neurotherapeutics, 14(3), 734-740.
[36] Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., ... & Liechti, M. E. (2021). Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 46(3), 537-544.
[37] Hutten, N. R., Mason, N. L., Dolder, P. C., & Kuypers, K. P. (2020). Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems. Microdosing Bulletin, 1(1), 1-7.
[38] Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268-1278.
[39] Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., ... & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in

patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180.

[40] Gukasyan, N., & Nayak, S. M. (2022). Psychedelic therapy for depression: considerations and challenges. Neuropsychopharmacology, 47(1), 1-3.

[41] Bogenschutz, M. P., & Ross, S. (2018). Therapeutic applications of classic hallucinogens. In Behavioral Neurobiology of Psychedelic Drugs (pp. 361-391). Springer, Berlin, Heidelberg.

[42] Nutt, D., Erritzoe, D., & Carhart-Harris, R. (2020). Psychedelic psychiatry's brave new world. Cell, 181(1), 24-28.

[43] Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., ... & Work Group on Biomarkers and Novel Treatments. (2020). Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry, 177(5), 391-410.